Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab - CA224-087

Updated: 3 August, 2020   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1


  • Gender(s)

  • 18+

    Age Range

  • 1


  • Recruiting

Treatment Options

Study Arms
Experimental: nivolumab + relatlimab + rHuPH20
Drug: relatlimab Drug: rHuPH20 Drug: nivolumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of (unresectable and/or metastatic) advanced solid tumors - Melanoma - Metastatic squamous or non- squamous non-small cell lung cancer (NSCLC) - Gastric adenocarcinoma (includes gastro-esophageal junction) - Hepatocellular carcinoma (HCC) - Squamous cell carcinoma of the head and neck (SCCHN) - Renal cell carcinoma (RCC) - Bladder cancer - Participants must have received available standard therapies - Women and men must agree to follow instructions for method of contraception - Measureable disease as per RECIST version 1.1 criteria - Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: - Participants must not have active brain metastases or leptomeningeal metastases - Participants with HCC must not have any history of hepatic encephalopathy, any prior (within 1 year) or current clinically significant ascites - History of allergy or hypersensitivity to study drug components - Participants with serious or uncontrolled cardiovascular disease - Excluding patients with serious or uncontrolled medical disorders - Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment - Participants with an active, known, or suspected autoimmune disease - Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population Other protocol defined inclusion/exclusion Criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com